Heron Therapeutics Inc (NASDAQ:HRTX) Given Consensus Recommendation of “Hold” by Brokerages

Heron Therapeutics Inc (NASDAQ:HRTX) has earned an average rating of “Hold” from the nine ratings firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $58.00.

A number of equities research analysts have issued reports on the company. Northland Securities reaffirmed a “buy” rating and set a $55.00 target price on shares of Heron Therapeutics in a research report on Monday, August 5th. Cowen reaffirmed a “buy” rating on shares of Heron Therapeutics in a research report on Thursday, May 9th. BidaskClub raised Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 10th. Evercore ISI reaffirmed a “buy” rating and set a $75.00 target price on shares of Heron Therapeutics in a research report on Tuesday, August 13th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $38.00 target price on shares of Heron Therapeutics in a research report on Monday, August 5th.

In other Heron Therapeutics news, Director John Poyhonen acquired 3,000 shares of Heron Therapeutics stock in a transaction dated Wednesday, May 22nd. The stock was bought at an average cost of $17.55 per share, with a total value of $52,650.00. Following the completion of the transaction, the director now owns 13,000 shares of the company’s stock, valued at $228,150. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 12.56% of the stock is currently owned by corporate insiders.



Institutional investors and hedge funds have recently bought and sold shares of the company. Meadow Creek Investment Management LLC bought a new stake in shares of Heron Therapeutics in the second quarter valued at approximately $27,000. Parallel Advisors LLC boosted its position in shares of Heron Therapeutics by 247.4% in the first quarter. Parallel Advisors LLC now owns 1,685 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 1,200 shares during the period. Pearl River Capital LLC boosted its position in shares of Heron Therapeutics by 1,900.0% in the first quarter. Pearl River Capital LLC now owns 2,000 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 1,900 shares during the period. Lindbrook Capital LLC bought a new stake in shares of Heron Therapeutics in the second quarter valued at approximately $37,000. Finally, US Bancorp DE boosted its position in shares of Heron Therapeutics by 75.6% in the second quarter. US Bancorp DE now owns 4,108 shares of the biotechnology company’s stock valued at $76,000 after acquiring an additional 1,769 shares during the period.

Heron Therapeutics stock traded up $0.28 during trading hours on Friday, reaching $17.18. 611,600 shares of the company were exchanged, compared to its average volume of 871,515. The firm has a market cap of $1.35 billion, a price-to-earnings ratio of -7.04 and a beta of 1.49. The company has a current ratio of 4.01, a quick ratio of 3.70 and a debt-to-equity ratio of 0.04. The stock has a 50-day moving average of $17.97 and a 200 day moving average of $21.39. Heron Therapeutics has a 12 month low of $15.68 and a 12 month high of $41.10.

Heron Therapeutics (NASDAQ:HRTX) last announced its earnings results on Monday, August 5th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.02. The firm had revenue of $36.66 million during the quarter, compared to analysts’ expectations of $31.04 million. Heron Therapeutics had a negative return on equity of 56.89% and a negative net margin of 172.07%. As a group, research analysts forecast that Heron Therapeutics will post -2.73 EPS for the current year.

About Heron Therapeutics

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Featured Story: Federal Reserve

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.